论文部分内容阅读
目的探讨胞必佳胸腔内注射对顽固性气胸的治疗作用。方法将96例顽固性气胸患者随机分为观察组(胞必佳组)和对照组(重组人白细胞介素-2组),在胸腔闭式引流的基础上,分别往胸腔内注入胞必佳400μg或重组人白细胞介素-2 150万IU。结果观察组用药后平均终止漏气时间为(1.89±0.95)d,有效率为91.7%,1次注药成功率为52.1%;对照组用药后平均终止漏气时间为(3.78±0.89)d,有效率为70.8%,1次注药成功率为20.8%,两组比较差异有统计学意义(P<0.05)。两组不良反应发生情况比较差异未见统计学意义(P>0.05),且均对外周血象无明显影响。结论胞必佳胸腔内注射治疗顽固性气胸效果佳,不良反应少。
Objective To investigate the therapeutic effect of intrapleural intrapleural injection of refractory pneumothorax. Methods Ninety-six patients with intractable pneumothorax were randomly divided into observation group (control group) and control group (recombinant human interleukin-2 group). On the basis of closed drainage, 400 μg or recombinant human interleukin-2 1.5 million IU. Results The mean time to end of leak in the observation group was (1.89 ± 0.95) d, the effective rate was 91.7% and the success rate of one injection was 52.1%. The mean time to end of leakage in the control group was (3.78 ± 0.89) d , The effective rate was 70.8% and the success rate of one injection was 20.8%. The difference between the two groups was statistically significant (P <0.05). No significant difference was found in adverse reactions between the two groups (P> 0.05), and no significant effect on peripheral blood. Conclusion Intracellular pleural injection of intrathoracic refractory pneumothorax good effect, less adverse reactions.